These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 33595834)

  • 1. Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study.
    Perlman A; Goldstein R; Choshen Cohen L; Hirsh-Raccah B; Hakimian D; Matok I; Kalish Y; Singer DE; Muszkat M
    CNS Drugs; 2021 Mar; 35(3):305-316. PubMed ID: 33595834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations.
    Goldstein R; Rabkin N; Buchman N; Jacobs AR; Sandouka K; Raccah B; Fisher Negev T; Matok I; Bialer M; Muszkat M
    CNS Drugs; 2024 May; 38(5):399-408. PubMed ID: 38520503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events.
    Acton EK; Hennessy S; Gelfand MA; Leonard CE; Bilker WB; Shu D; Willis AW; Kasner SE
    JAMA Neurol; 2024 Aug; 81(8):835-844. PubMed ID: 38976246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective.
    Ranzato F; Roberti R; Deluca C; Carta M; Peretti A; Polo D; Perini F; Russo E; Di Gennaro G
    Neurol Sci; 2024 Jan; 45(1):277-288. PubMed ID: 37548755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
    Mueller T; Alvarez-Madrazo S; Robertson C; Bennie M
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1378-1386. PubMed ID: 28752670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
    Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
    CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment.
    Goldstein R; Jacobs AR; Zighan L; Gronich N; Bialer M; Muszkat M
    CNS Drugs; 2023 Mar; 37(3):203-214. PubMed ID: 36869199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam.
    Mavri A; Ilc S
    Sci Rep; 2023 Jun; 13(1):9257. PubMed ID: 37286616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
    Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.